JP2023501722A5 - - Google Patents
Info
- Publication number
- JP2023501722A5 JP2023501722A5 JP2022528263A JP2022528263A JP2023501722A5 JP 2023501722 A5 JP2023501722 A5 JP 2023501722A5 JP 2022528263 A JP2022528263 A JP 2022528263A JP 2022528263 A JP2022528263 A JP 2022528263A JP 2023501722 A5 JP2023501722 A5 JP 2023501722A5
- Authority
- JP
- Japan
- Prior art keywords
- subfamily
- tcrβ
- subject
- cancer
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024198993A JP2025024094A (ja) | 2019-11-14 | 2024-11-14 | 抗ｔｃｒ抗体分子およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962935172P | 2019-11-14 | 2019-11-14 | |
| US62/935,172 | 2019-11-14 | ||
| US202062956969P | 2020-01-03 | 2020-01-03 | |
| US62/956,969 | 2020-01-03 | ||
| PCT/US2020/060557 WO2021097325A1 (en) | 2019-11-14 | 2020-11-13 | Anti-tcr antibody molecules and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024198993A Division JP2025024094A (ja) | 2019-11-14 | 2024-11-14 | 抗ｔｃｒ抗体分子およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023501722A JP2023501722A (ja) | 2023-01-18 |
| JP2023501722A5 true JP2023501722A5 (enExample) | 2024-05-13 |
| JP7590430B2 JP7590430B2 (ja) | 2024-11-26 |
Family
ID=75912403
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022528263A Active JP7590430B2 (ja) | 2019-11-14 | 2020-11-13 | 抗ｔｃｒ抗体分子およびその使用 |
| JP2024198993A Pending JP2025024094A (ja) | 2019-11-14 | 2024-11-14 | 抗ｔｃｒ抗体分子およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024198993A Pending JP2025024094A (ja) | 2019-11-14 | 2024-11-14 | 抗ｔｃｒ抗体分子およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230048244A1 (enExample) |
| EP (1) | EP4058483A4 (enExample) |
| JP (2) | JP7590430B2 (enExample) |
| CN (1) | CN115003698A (enExample) |
| AU (2) | AU2020384369B2 (enExample) |
| CA (1) | CA3160997A1 (enExample) |
| GB (1) | GB2607452B (enExample) |
| WO (1) | WO2021097325A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| CA3105448A1 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| GB2599228B (en) | 2019-02-21 | 2024-02-07 | Marengo Therapeutics Inc | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| CN119039441A (zh) | 2019-02-21 | 2024-11-29 | 马伦戈治疗公司 | 与nkp30结合的抗体分子及其用途 |
| AU2020416273A1 (en) | 2020-01-03 | 2022-07-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| EP4413044A4 (en) * | 2021-10-07 | 2025-10-22 | Nat Res Council Canada | ANTI-CD3 MONOCLONAL ANTIBODIES AND THERAPEUTIC CONSTRUCTS |
| EP4426321A4 (en) * | 2021-11-05 | 2025-12-10 | Marengo Therapeutics Inc | IMMUNE CELL POPULATIONS AND THEIR USES |
| KR20250143365A (ko) * | 2022-10-12 | 2025-10-01 | 마렝고 테라퓨틱스, 인크. | Tcr에 결합하는 다기능성 분자 및 이의 용도 |
| AU2024240821A1 (en) | 2023-03-23 | 2025-11-06 | Bodhi Bio Llc | Compositions and methods for antigen-specific therapy |
| WO2025051339A1 (en) * | 2023-09-05 | 2025-03-13 | Tiber Biotech Srl | SINGLE-CHAIN VARIABLE FRAGMENT AND MOLECULES DERIVING THEREFROM THAT BIND FRAGMENT TRVB5-1 OF THE β CHAIN OF HUMAN T-CELL RECEPTOR |
| WO2025245071A1 (en) * | 2024-05-21 | 2025-11-27 | Marengo Therapeutics, Inc. | Multifunctional molecules binding to tcr and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766947A (en) * | 1988-12-14 | 1998-06-16 | Astra Ab | Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor |
| US5776459A (en) * | 1989-07-19 | 1998-07-07 | Connetics Corporation | TCR V beta 5 peptides |
| WO2000006733A2 (en) * | 1998-07-29 | 2000-02-10 | Heska Corporation | T cell receptor proteins, nucleic acid molecules, and uses thereof |
| JP5184732B2 (ja) * | 2000-06-19 | 2013-04-17 | ベス イスラエル デアコネス メディカル センター | Ｔ細胞亜集団に特異的なモノクローナル抗体およびポリクローナル抗体の組成物および使用方法 |
| GB0328363D0 (en) * | 2003-12-06 | 2004-01-14 | Imp College Innovations Ltd | Therapeutically useful molecules |
| US9018006B2 (en) * | 2010-07-23 | 2015-04-28 | The University Of Toledo | Stable Tregs and related materials and methods |
| DK2623604T3 (da) * | 2012-02-02 | 2015-06-01 | Baylor College Medicine | Adenovirusbaseret biologisk afgivelses- og ekspressionssystem til anvendelse ved behandling af osteoartrose |
| MX384246B (es) * | 2013-10-30 | 2025-03-14 | Genzyme Corp | POLIPÉPTIDO DE UNIÓN A TCR ALFA BETA PARA USARSE EN LA DISMINUCIÓN DE LINFOCITOS TAß. |
| JP2018517712A (ja) * | 2015-06-01 | 2018-07-05 | メディジーン イミュノテラピーズ ゲーエムベーハー | Ｔ細胞受容体特異的抗体 |
| CA3105448A1 (en) * | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| GB2595980B (en) * | 2019-01-04 | 2023-06-14 | Marengo Therapeutics Inc | Anti-TCR antibody molecules and uses thereof |
| EP3927431A1 (en) * | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| AU2020416273A1 (en) * | 2020-01-03 | 2022-07-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| EP4426321A4 (en) * | 2021-11-05 | 2025-12-10 | Marengo Therapeutics Inc | IMMUNE CELL POPULATIONS AND THEIR USES |
-
2020
- 2020-11-13 WO PCT/US2020/060557 patent/WO2021097325A1/en not_active Ceased
- 2020-11-13 EP EP20886222.7A patent/EP4058483A4/en active Pending
- 2020-11-13 AU AU2020384369A patent/AU2020384369B2/en active Active
- 2020-11-13 CN CN202080093361.9A patent/CN115003698A/zh active Pending
- 2020-11-13 GB GB2208378.6A patent/GB2607452B/en active Active
- 2020-11-13 CA CA3160997A patent/CA3160997A1/en active Pending
- 2020-11-13 JP JP2022528263A patent/JP7590430B2/ja active Active
-
2022
- 2022-05-16 US US17/745,456 patent/US20230048244A1/en active Pending
-
2024
- 2024-11-14 JP JP2024198993A patent/JP2025024094A/ja active Pending
-
2025
- 2025-05-12 AU AU2025203410A patent/AU2025203410A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023501722A5 (enExample) | ||
| GB2607452A (en) | Anti-TCR antibody molecules and uses thereof | |
| JP7599205B2 (ja) | 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化 | |
| JP7457007B2 (ja) | 二重作用ＣＤ１ｄ免疫グロブリン | |
| JP7303749B2 (ja) | Ｔｉｍ－１を標的とするキメラ抗原受容体 | |
| JP6867347B2 (ja) | 免疫療法のためのエンゲージャー細胞 | |
| JP2022550899A5 (enExample) | ||
| US9777073B2 (en) | Construction and application of bispecific antibody EpCAM×CD3 | |
| JP2022541441A5 (enExample) | ||
| US20160000842A1 (en) | Oncolytic virus | |
| KR20190091497A (ko) | 고형 종양으로의 침투를 위한 세포 시스템과 관련된 조성물 및 방법 | |
| IL271325B1 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| WO2020057641A1 (zh) | 表达有趋化因子的细胞及用途 | |
| CN113784980B (zh) | 人源化抗Claudin18.2嵌合抗原受体及其用途 | |
| CN106536558A (zh) | 转基因遗传标签和使用的方法 | |
| US20220152101A1 (en) | Cellular immunotherapy combination | |
| US20180028631A1 (en) | Anti-ssea4 chimeric antigen receptors and their use for treating cancer | |
| US20230398216A1 (en) | Chimeric activation receptors | |
| JP2023548974A (ja) | Ｔ細胞抗原カプラを含む細胞及びその使用 | |
| JP2023550148A5 (enExample) | ||
| WO2022057941A1 (zh) | 表达il-7r结合蛋白的免疫效应细胞 | |
| KR20210145179A (ko) | 스위치 가능한 키메라 항원 수용체-조작된 인간 자연 살해 세포 | |
| JP2024540347A (ja) | 記憶ｎｋ細胞と抗癌性二重特異性分子とによる組み合わせ癌療法 | |
| CN115315270A (zh) | 工程化免疫细胞 | |
| CN114437214B (zh) | 靶向lir1的抗体及其用途 |